The Quantellect read.As of Nov 19, 2026, 3 active firms cover Keros Therapeutics Inc: 2 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $18.00 to $23.00, so the covering firms are broadly aligned. The average target of $20.00 sits 67% above the current $12.01. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.51 next quarter toward $-5.96 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy267%
Neutral133%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$20.00
+66.5% upside
Average target across 3 active firms as of Nov 19, 2026 vs $12.01 current
Highest Target$23.00
Average Target$20.00
Lowest Target$18.00
Detailed analyst forecasts for KROS
Showing 1–2 of 2 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 2 of 3 active firms rate KROS a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
KROS EPS & revenue forecast
EPS · NEXT QUARTER
$-1.51
Range $-1.51 – $-1.51 · 1 analysts · +25% YoY
Next period, 1 analysts expect Keros Therapeutics Inc to earn $-1.51 a share (range $-1.51 – $-1.51), versus $-1.21 a year earlier. Full-year consensus is $-3.35, growing to $-5.96 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year. Full-year consensus is $41.3M, rising to $13.7M next year.
Top analysts covering Keros Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KROS.
#1
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$25.00+108.2% to target
Overall win rate
45%
+ Follow
#2
Julian Harrison
BTIG · Rank #183
Neutral
No targeton KROS
Overall win rate
41%
+ Follow
#3
Vamil Divan
Guggenheim · Rank #211
Neutral
No targeton KROS
Overall win rate
48%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #223
Buy
$26.00+116.5% to target
Overall win rate
38%
+ Follow
#5
Andres Y. Maldonado
HC Wainwright & Co. · Rank #288
Buy
$20.00+66.5% to target
Overall win rate
39%
+ Follow
KROS stock forecast FAQ
What is KROS's average 12-month price target?+
The 3 active firms with a live target average $20.00 for Keros Therapeutics Inc over the next 12 months, ranging from a $23.00 high to a $18.00 low, as of Nov 19, 2026.
Is KROS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for KROS?+
The Street-high target is $23.00, and the Street-low is $18.00 (Wells Fargo). The average of all 3 active-firm targets is $20.00.
How many active Wall Street firms cover KROS?+
3 active firms have a recognized rating on Keros Therapeutics Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering KROS?+
Among analysts who currently cover KROS, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #73). Their current call is Buy with a $25.00 target.
What is Keros Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.51 per share (range $-1.51 – $-1.51) across 1 analysts. Full-year EPS is projected at $-3.35, rising to $-5.96 the following year.
How much revenue is Keros Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $41.3M, growing to $13.7M next year.
Have analysts been upgrading or downgrading KROS lately?+
As of Nov 19, 2026, 2 of 3 active firms rate KROS a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KROS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.